Wallstreetbets

Thinly traded biotech Prothena Corporation plc (PRTA) is up about 5% in the pre-market on light volume after announcing a $1.2 billion deal where Novo Nordisk will buy Prothena's heart drug. The deal includes $100 million in an upfront and near-term milestone payments, extending PRTA's cash runway by close to a year. PRTA started going parabolic on Friday, hitting a new high of $67.08 on Friday before closing up 7% to $59.24. With this news hitting the pre-market and the light volume, this could cause a major short squeeze. Yahoo Finance stats show that PRTA has 2.14 million in short interest. This isn't too large, comprising 9% of the 22.71 million float. But PRTA is a very thinly traded stock with less than 500,000 shares traded in a day on average. If shorts capitulate like they started to do on Friday, this could cause a major squeeze. Short interest has been in the 2 million range since the start of April, slightly growing from there. With the stock price having nearl

At the start of this week we talked about the short squeeze potential on  Alector, Inc. (ALEC) . That potential has just gotten bigger as the stock has steadily risen from $35 during a shaky week for the markets and is set to open above $40 on Friday. ALEC rose 57% last Friday after signing a $2.2 billion deal with  GlaxoSmithKline (GSK)  to co-develop progranulin-elevating monoclonal antibodies, AL001 and AL101, for a range of neurodegenerative diseases. This deal includes a $700 million upfront payment, including $500 million coming in Q3, which is key to understanding the potential of the short squeeze. According to  Yahoo Finance , ALEC has 6.7 million in short interest. This is 12% of the float, but consider that volume has tapered off quite a bit this week to an average of 2 million shares traded on Wednesday and Thursday. So it will get harder and harder to cover that short as volume goes down but price goes up.  What is going on here? Certain funds were shorting ALEC not becaus

  We have written several blogs this month about our top microcap short squeeze picks to try to take down notorious small cap manipulator Sabby Management, starting with the one on  June 15th . This week we talked about how  Auddia Inc. (AUUD)  and  Cuentas Inc. (CUEN)  showed many similarities to  Alfi, Inc. (ALF),  which has since broken out to as high as $20 from $7 in a short squeeze as we predicted. While  1847 Goedeker Inc. (GOED)  has also performed well, unfortunately  BriaCell Therapeutics Corp. (BCTX) (BCT.V)  and  GeoVax Labs, Inc. (GOVX)  have not. So we are putting those two on the backburner while focusing on AUUD and CUEN. In the short squeeze game it's always important to strike while hot. Sabby and these other short selling scumbags are all shorting the same set of stocks. So when one takes off, that makes the others more susceptible to a squeeze as multiple positions run against them. While we have had a focus on small caps recently, one stock we have to highlight

We have written several blogs this month about our top microcap short squeeze picks to try to take down notorious small cap manipulator Sabby Management, starting with the one on  June 15th . Yesterday we talked about how  Auddia Inc. (AUUD)  and  Cuentas Inc. (CUEN)  showed many similarities to  Alfi, Inc. (ALF),  which has since broken out to as high as $20 from $7 in a short squeeze as we predicted. While  1847 Goedeker Inc. (GOED)  has also performed well, unfortunately  BriaCell Therapeutics Corp. (BCTX) (BCT.V) and GeoVax Labs, Inc. (GOVX) have not. So we are putting those two on the backburner while focusing on AUUD and CUEN. In the short squeeze game it's always important to strike while hot. Sabby and these other short selling scumbags are all shorting the same set of stocks. So when one takes off, that makes the others more susceptible to a squeeze as multiple positions run against them. The evidence on AUUD and CUEN is fierce. Both stocks were aligned very closely in tr